Skip to main content
. Author manuscript; available in PMC: 2016 Sep 19.
Published in final edited form as: Lancet. 2015 Jul 2;386(9999):1147–1155. doi: 10.1016/S0140-6736(15)61120-5

Figure 4.

Figure 4

(A) Median percent change (±interquartile range) in osteocalcin and C-telopeptide from baseline to 48-months. *P<0.0001 versus combination-to-denosumab at months 24, 25, 30,36,42,48. #P<0.0001 versus teriparatide-to-denosumab at months 24,30,36,42,48, P=NS at month 25. %P<0.0001 versus teriparatide-to-denosumab at months 25,30,36,42,48, P=NS at month 24.

(B) Median percent change (interquartile range) in osteocalcin and C-telopeptide from baseline to 24-48 months in the teriparatide-to-denosumab group and combination-to-denosumab group. &P<0.05 compared to combination-to-denosumab at the indicated time points.